Meeting
2019 Genitourinary Cancers Symposium
Phase I/II dose-escalation trial of fractionated dose 177Lu-J591 plus 177Lu-PSMA-617 for metastatic castration-resistant prostate cancer (mCRPC).
Authors
Scott T. Tagawa
Division of Hematology & Medical Oncology, Meyer Cancer Center, Department of Urology, Weill Cornell Medical College & New York-Presbyterian Hospital, New York, NY
Scott T. Tagawa , Muhammad Junaid Niaz , Joseph Osborne , Shankar Vallabhajosula , Himisha Beltran , Lauren Christine Harshman , David M. Nanus , Ana M. Molina , Bishoy Morris Faltas , Amy Hackett , Lauren Gracey , Jyothi Sreekumar , John Babich , Karla V. Ballman , Neil Harrison Bander
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Trials in Progress Poster Session
Session Title
Trials in Progress Poster Session A: Prostate Cancer
Track
Prostate Cancer,Prostate Cancer
Sub Track
Prostate Cancer - Advanced Disease
Clinical Trial Registration Number
NCT03545165
Citation
J Clin Oncol 37, 2019 (suppl 7S; abstr TPS339)
DOI
10.1200/JCO.2019.37.7_suppl.TPS339
Abstract #
TPS339
Poster Bd #
N15
Abstract Disclosures
Similar Posters
Poster
2018 Genitourinary Cancers Symposium
Phase I dose-escalation study of 225Ac-J591 for progressive metastatic castration resistant prostate cancer (mCRPC).
First Author: Scott T. Tagawa
Poster
2017 ASCO Annual Meeting
Phase I dose-escalation study of fractionated-dose 177Lu-PSMA-617 for progressive metastatic castration resistant prostate cancer (mCRPC).
First Author: Scott T. Tagawa
Poster
2020 Genitourinary Cancers Symposium
Dose-escalation results of a phase I study of 225Ac-J591 for progressive metastatic castration resistant prostate cancer (mCRPC).
First Author: Scott T. Tagawa
Poster
2024 ASCO Genitourinary Cancers Symposium
A phase 1/2 study of ONCT-534, a dual-action androgen receptor inhibitor (DAARI), in patients with metastatic castration-resistant prostate cancer.
First Author: Evan Y. Yu